Article
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
PloS one - 1 Jan 2013
Bogani Costanza, Bartalucci Niccolò, Martinelli Serena, Tozzi Lorenzo, Guglielmelli Paola, Bosi Alberto, Vannucchi Alessandro M
Abstract excerpt
BACKGROUND: Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation. Recent clinical trials with JAK2 inhibitors showed significant improvements in splenomegaly and constitutional symptoms in patients with myelofibrosis but meaningful molecular responses were not documented. Accordingly, there remains a need for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.